Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results.

Gong J, Zhou J, Yuan D, Ma X, Vishwamitra D, Hilder B, Masterson TJ, Tolbert J, Renaud T, Heuck C, Kane C, Samtani MN, Girgis S, Haddish-Berhane N, Berdeja J, Krishnan A, Ouellet D

Open source

DOI: 10.1002/cpt.70004
Published: 2025 Oct
Container: Clinical pharmacology and therapeutics
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cpt.70004,
  title = {Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results.},
  author = {Gong J and Zhou J and Yuan D and Ma X and Vishwamitra D and Hilder B and Masterson TJ and Tolbert J and Renaud T and Heuck C and Kane C and Samtani MN and Girgis S and Haddish-Berhane N and Berdeja J and Krishnan A and Ouellet D},
  year = {2025},
  journal = {Clinical pharmacology and therapeutics},
  doi = {10.1002/cpt.70004},
  url = {https://doi.org/10.1002/cpt.70004}
}

RIS

TY  - JOUR
TI  - Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results.
AU  - Gong J
AU  - Zhou J
AU  - Yuan D
AU  - Ma X
AU  - Vishwamitra D
AU  - Hilder B
AU  - Masterson TJ
AU  - Tolbert J
AU  - Renaud T
AU  - Heuck C
AU  - Kane C
AU  - Samtani MN
AU  - Girgis S
AU  - Haddish-Berhane N
AU  - Berdeja J
AU  - Krishnan A
AU  - Ouellet D
PY  - 2025
JO  - Clinical pharmacology and therapeutics
DO  - 10.1002/cpt.70004
UR  - https://doi.org/10.1002/cpt.70004
ER  -

APA

J, G., J, Z., D, Y., X, M., D, V., B, H., TJ, M., J, T., T, R., C, H., C, K., MN, S., S, G., N, H., J, B., A, K., & D, O. (2025). Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results.. Clinical pharmacology and therapeutics. https://doi.org/10.1002/cpt.70004

Source records

pubmed · retrieved 2026-09-25T20:14:07.838Z
europe-pmc · retrieved 2026-09-25T20:14:07.852Z